Cir­cled by ri­val phar­ma gi­ants and a biotech pow­er­house, Ko­di­ak asks for a $100M-plus IPO for new eye drug

Ko­di­ak Sci­ences was nev­er one of those biotechs that liked to tout every fi­nanc­ing round or talk up its drug prospects. Helmed by biotech vet and for­mer MPM ven­ture part­ner Vic­tor Perl­roth, it turns out the biotech has been steadi­ly jock­ey­ing a new oph­thal­mol­o­gy drug right to the thresh­old of a soon-to-launch Phase II tri­al. And he’s aim­ing straight at cut­ting the legs out from un­der a block­buster fierce­ly de­fend­ed by one of the tough­est play­ers in drug R&D — once he com­pletes a $100 mil­lion-plus IPO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER